Squarepoint
BRNS

Squarepoint’s Barinthus Biotherapeutics BRNS Stock Holding History

Squarepoint’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$420K – 2937
2021
Q2 		$420K Buy
+25,000
New +$370K ﹤0.01% 2267

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's BRNS Position: Q3 2021 in Review

Squarepoint sold out of Barinthus Biotherapeutics (BRNS) in Q3 2021, closing a stake of 25,000 shares — an estimated $420K sold.

Squarepoint first reported a position in BRNS in Q2 2021 and held it in 1 quarter. The position peaked at $420K in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q3 2021.

  • Squarepoint reported no remaining Barinthus Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 25,000 Barinthus Biotherapeutics shares in Q3 2021, an estimated $420K.
  • Squarepoint first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Squarepoint's Barinthus Biotherapeutics position peaked at $420K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.